Kurosawa Shuhei, Yoshimura Yukihiro, Takada Yusuke, Yokota Takako, Hibi Masaki, Hirahara Ayumi, Yoshida Tsutomu, Okubo So, Masuda Moe, So Yuna, Miyata Nobuyuki, Nakayama Hitomi, Sakurai Aki, Sato Kosuke, Ito Chisako, Aisa Yoshinobu, Nakazato Tomonori
Department of Hematology.
Division of Infectious Disease, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
AIDS. 2024 Sep 1;38(11):1627-1637. doi: 10.1097/QAD.0000000000003949. Epub 2024 Jun 24.
OBJECTIVES: To address the paucity of HIV-related lymphoma (HRL)-specific prognostic scores for the Japanese population by analyzing domestic cases of HRL and constructing a predictive model. DESIGN: A single-center retrospective study coupled with a review of case reports of HRL. METHODS: We reviewed all patients with HRL treated at our hospital between 2007 and 2023 and conducted a comprehensive search for case reports of HRL from Japan using public databases. A multivariate analysis for overall survival (OS) was performed using clinical parameters, leading to the formulation of the HIV-Japanese Prognostic Index (HIV-JPI). RESULTS: A total of 19 patients with HRL were identified in our institution, whereas the literature review yielded 44 cases. In the HIV-JPI, a weighted score of 1 was assigned to the following factors: age at least 45 years, HIV-RNA at least 8.0×10 4 copies/ml, Epstein-Barr virus-encoded small RNA positivity, and Ann Arbor classification stage IV. The overall score ranged from 0 to 4. We defined the low-risk group as scores ranging from 0 to 2 and the high-risk group as scores ranging from 3 to 4. The 3-year OS probability of the high-risk group [30.8%; 95% confidence interval (CI): 9.5-55.4%) was significantly poorer than that of the low-risk group (76.8%; 95% CI: 52.8-89.7%; P < 0.01). CONCLUSION: This retrospective analysis established pivotal prognostic factors for HRL in Japanese patients. The HIV-JPI, derived exclusively from Japanese patients, highlights the potential for stratified treatments and emphasizes the need for broader studies to further refine this clinical prediction model.
目的:通过分析日本国内的HIV相关淋巴瘤(HRL)病例并构建预测模型,以解决日本人群中HRL特异性预后评分的匮乏问题。 设计:一项单中心回顾性研究,并对HRL病例报告进行综述。 方法:我们回顾了2007年至2023年期间在我院接受治疗的所有HRL患者,并使用公共数据库对日本的HRL病例报告进行了全面检索。使用临床参数对总生存期(OS)进行多变量分析,从而制定了HIV-日本预后指数(HIV-JPI)。 结果:我们机构共确定了19例HRL患者,而文献综述得出44例。在HIV-JPI中,以下因素被赋予加权分数1分:年龄至少45岁、HIV-RNA至少8.0×10⁴拷贝/ml、爱泼斯坦-巴尔病毒编码的小RNA阳性以及Ann Arbor分期IV期。总分范围为0至4分。我们将低风险组定义为分数范围为0至2分,高风险组定义为分数范围为3至4分。高风险组的3年总生存率[30.8%;95%置信区间(CI):9.5 - 55.4%]显著低于低风险组(76.8%;95% CI:52.8 - 89.7%;P < 0.01)。 结论:这项回顾性分析确定了日本患者HRL的关键预后因素。专门源自日本患者的HIV-JPI突出了分层治疗的潜力,并强调需要进行更广泛的研究以进一步完善这一临床预测模型。
AIDS. 2024-9-1
Front Cell Infect Microbiol. 2022
Zhonghua Xue Ye Xue Za Zhi. 2022-3-14
IJU Case Rep. 2022-10-5
Curr Opin Oncol. 2022-9-1
Front Cell Infect Microbiol. 2022
Glob Health Med. 2022-2-28
Blood. 2022-2-17